


ISMP Medication Error Reporting

Rita K. Jew, Pharm.D., MBA, BCPPS, FASHP

President

Institute for Safe Medication Practices (ISMP)

ISMP National Medication Errors Reporting Program (MERP)





What Do We Do With the Reports?



- Healthcare
 practitioners/
 consumers submit
 medication error
 reports through
 ISMP's error reporting
 programs
- –Staff follow up with reporter



- Investigate to determine cause & severity of error
- –Work with our network of advisors to assess implication & risks





- Promptly inform healthcare community through:
- Newsletters
- Educational events
- Alerts
- Articles in trade journals



- Interacts with FDA & USP to influence regulatory change
- -Works with manufacturers, standards organizations, professional/trade organizations & healthcare community to effect change
- Provides proactive risk assessments and educational services







Who Does ISMP Work With?

- U.S. Food & Drug Administration (FDA)
- United States Pharmacopeia (USP)
- The Joint Commission
- National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)
- National Patient Safety Collaborative
- Medical product industry



U.S. Food & Drug Administration (FDA)

- Tall man (mixed case) lettering for look-alike drug names (EPINEPHrine - ePHEDrine)
- FDA Barcode Rule
- Vincristine in minibag
- FDA Guidance: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors





[4/21/22] FDA worked with drug application holders to remove instructions for preparation of vinca alkaloids by syringe and to recommend preparation in intravenous infusion bags only. These labeling updates are complete, and the updated prescribing information for vinca alkaloids now contains instructions for health care professionals to only prepare these drugs in intravenous infusion bags.

f Share y Tweet in Linkedin Email Print





August 05, 2022

IMPORTANT PRESCRIBING AND DISPENSING INFORMATION

Subject: Minimizing wrong dose medication errors and revised Patients, Parents and Caregivers Fact Sheet for PAXLOVID (nirmatrelvir tablets; ritonavir tablets).

Dear Healthcare Provider,

FDA alerts health care professionals of compatibility issues with prefilled glass syringes and certain Luer-activated valve (LAV) connectors



[11/22/2022] FDA is alerting health care professionals that certain Luer-activated valve (LAV) connectors (sometimes referred to as needleless Luer access devices or needleless connectors) with internal pin designs may not be compatible with prefilled glass syringes (e.g., <u>naloxone</u> prefilled glass syringes). The internal pin of the LAV connector may



United States Pharmacopeia General Chapter <7>

<7> LABELING This general chapter provides definitions and standards for labeling of official articles 7 Labeling standards for an article recognized in USP-NF are expressed in the article's 8 monograph and applicable general chapters. It is intended that all articles in USP or NF will b 9 subject to the labeling requirements specified in this chapter by means of a provision in General 10 Notices, 10 Preservation, Packaging, Storage, and Labeling, unless different requirements are 11 provided in a specific monograph. As with compendial standards for naming identity strength 12 quality, and purity, compendial requirements for labeling have a role in the adulteration and 13 misbranding provisions of federal law [see the Federal Food, Drug, and Cosmetic Act (FDCA) 14 sections 501(b), 502(e)(3)(b), 502(g), and 502(h)]. Exceptions or additional requirements 15 specific to animal drug products and compounded preparations are provided in separate 16 sections. Vaccine labeling is not included in this general chapter The term "labeling" includes all labels and other written, printed, or graphic matter on ar 21 article's immediate container or on, or in, any package or wrapper in which it is enclosed, except 22 any outer shipping container. The term "label" is that part of the labeling on the immediate A shipping container that contains a single article, unless the container also is essentially the 25 immediate container or the outside of the consumer package, must be labeled with a minimum 26 of product identification (except for controlled substances), lot number, expiration date, and 27 conditions for storage and distribution Beyond-use dates (BUDs) and expiration dates are not the same. An expiration date 29 identifies the time during which a conventionally manufactured product, active ingredient, or 30 excipient can be expected to meet the requirements of a compendial monograph, if one exists, 31 provided it is kept under the prescribed storage conditions. The expiration date limits the time 32 during which the conventionally manufactured product, active pharmaceutical ingredient (API),



- Metric units
- Use of leading and terminal zeros
- Abbreviations of the word, "units"
- Quantity and total volume expression
- Ratio expressions
- Potassium chloride concentrate labeling
- Neuromuscular blocker labeling
- Expiration date labeling



The Joint Commission

- Elimination of "Rule of 6" for pediatric IV infusions
- Unsafe or do not use medical abbreviations
- Tall man (mixed case) lettering for look-alike drug names (EPINEPHrine ePHEDrine)
- Storage restrictions of concentrated potassium chloride implemented via NPSGs
- High-alert medications







CHARLOTTE OBSERVER

Potassium Kills Baby At

DURHAM — A premature baby has died at niversity Medical Center after receiving too much supplemental potassium, : representatives said.

The infant, a twin born at 26 weeks, died about 11 days ago, said Andrew Wallace, the medical center's vice president for health affe' s. The surviving twin was at

the last time he checked, he said, but hospital officials would not confirm that the twin was still there this weekend.

The baby died after receiving an infusion "to correct an imbalance of electrolytes," Wallace said.

An effort was being made to increase the baby's amount of potassium. Potassium, a major ele-ment of fluid inside cells, helps regulate several body functions. Wallace said no wrongdoing had

been found involving doctors or nurses. He said the medical center had changed its procedures as a result, but would not elaborate.
"The individuals involved are

lar occurrence in the future."

The statement was released after an anonymous caller reported the death to WTVD (channel 11) in Durham.

An autopsy was performed, Wallace said. But results aren't available yet.

neonatal intensive care unit is one of about 20 in the state. Roughly half of the babies treated come from other hospitals, but Wallace said he did not know if the twins were born at

He declined to identify the baby or say where the family lives.





Sentinel Event Alert

Issue 1 - February 28, 1998 **New Publication**

We are pleased to introduce the first issue of Sentinel Event Alert, a periodic publication dedicated to providing important information relating to the occurrence and management of sentinel events in Joint| Commission-accredited health care organizations. Sentinel Event Alert, to be published when appropriate as suggested by trend data, will provide ongoing communication regarding the Joint Commission's Sentinel Event Policy and Procedures, and most importantly, information about sentinel event prevention. It is our expectation and belief that in sharing information regarding the occurrence of sentinel events, we can ultimately reduce the frequency of medical errors and other adverse events.

Initially, Sentinel Event Alert will be mailed to the organization chief executive officers and Joint Commission survey coordinators, however, it is expected that eventually Sentinel Event Alert will be sent via broadcast fax. In the future, staff from the Joint Commission will be contacting your organization to collect appropriate fax and E-mail

While the topic of this first issue is particularly relevant to acute care facilities, we will share information of relevance to all accredited organizations in future issues.

"The way to prevent tragic deaths from accidental intravenous injection of concentrated KCI is excruciatingly simple -- organizations must take it off the floor stock of all units. It is one of the best examples I know of a 'forcing function' -- a procedure that makes a certain type of error impossible."

Lucian L. Leape, M.D. Harvard School of Public Health

Medication Error Prevention -- Potassium Chloride

In the two years since the Joint Commission enacted its Sentinel Event Policy, the Accreditation Committee of the Board of Commissioners has reviewed more than 200 sentinel events. The most common category of sentinel events was medication errors, and of those, the most frequently implicated drug was potassium chloride (KCI). The Joint Commission has reviewed 10 incidents of patient death resulting from misadministration of KCl, eight of which were the result of direct infusion of concentrated KCI. In all cases, a contributing factor identified was the availability of concentrated KCl on the nursing unit. In six of the eight cases, the KCI was mistaken for some other medication, primarily due to similarities in packaging and labeling. Most often, KCl was mistaken for sodium chloride, heparin or furosemide (Lasix).

Issue For Consideration

In light of this experience, the Joint Commission suggests that health care organizations NOT make concentrated KCl available outside of the pharmacy unless appropriate specific safeguards are in place.

"Unfortunately, there are too many in health care who feel that if it hasn't happened to them, the adverse experiences of others do not apply. That is why potassium chloride concentrate vials can still be found in patient care areas."


Michael Cohen, MS, FASHP, President, Institute for Safe Medication Practices



Preventing Catheter and Tubing Misconnections









Tylenol

- Influenced manufacturer recall due to confusing labels (2005)
- Removal of concentrated acetaminophen 100 mg/mL in pint bottles from market (2008)
- FDA safety alert on infant acetaminophen concentration (2011)
- Removal of 100 mg/mL drops from market







Labeling Changes

- Multiple mix-ups reported between Prolia and Udenyca prefilled syringes.
- Each packaged in similar green and white cartons, with the concentration listed in a green circle in the same location.
- Both products stocked in oncology and infusion centers, are refrigerated, and may be stored near each other.

ISMP Medication Safety Alert! 2019;24(17):1-2. ISMP Medication Safety Alert! 2020;25(2):4.





Questions?